Topic: small cell lung cancer
Is a drug's PD-1 or PD-L1 target the difference-maker when it comes to previously untreated small cell lung cancer? Merck doesn’t think so.
Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.
Here’s a familiar sentence: A combo of Imfinzi and tremelimumab missed its primary endpoint. This time, it applies to a small-cell lung cancer trial.
A Chinese company's producing a remdesivir generic. Daiichi expects $18 million in Enhertu Q1 sales. Tecentriq becomes seventh PD-1/L1 to enter China.
While a Keytruda-chemo combo showed significant improvement in cutting disease worsening or death in SCLC, it didn't extend patients' lives.
With the priority review, Imfinzi is now looking at a decision for use in frontline small cell lung cancer by the first quarter of 2020.
When AbbVie splashed $5.8 billion upfront and reserved another $4 billion in milestones for Stemcentrx in 2016, the primary focus was Rova-T.
Wall Street analysts pressed Merck for details about whether Keytruda can maintain strong growth as it faces rivals in lung and breast cancer.
Roche’s Tecentriq is the only I-O drug approved in small cell lung cancer. But it may soon have to make some room for AstraZeneca’s Imfinzi.
Roche’s Tecentriq is on a roll in Europe. After picking up a green light in breast cancer last week, it's now snagged a pair of go-aheads in lung cancer.